新股消息 | 康诺生物递表港交所 商业化药物为旗舰线粒体药物恩艾地®

Company Overview - Kangnuo Biopharmaceuticals is a biopharmaceutical company focused on the research, development, production, and commercialization of mitochondrial medicine and health products [2] - The company aims to address diseases caused by mitochondrial dysfunction, particularly in cardiovascular diseases, neurodegenerative diseases, reproductive health, and aging [2] - Kangnuo Biopharmaceuticals employs an integrated approach of "testing - intervention - assessment - re-intervention" to provide scientific solutions for extending healthy lifespan [2] - The flagship mitochondrial drug, Enai Di® (NAD+ injection), is the only NAD+ therapeutic drug approved both nationally and globally, establishing the company's leadership in the mitochondrial drug industry [2] Product Portfolio - The company has marketed and sold 20 drugs, including Enai Di® (NAD+ injection), Qianrongmei® (hyaluronidase injection), Tianshu® (kallikrein injection), and sodium nitroprusside injection [3] - In addition to these four main drugs, Kangnuo Biopharmaceuticals also sells 16 generic drugs covering four major therapeutic areas: digestive system, respiratory system, blood system, and nervous system [3] Financial Performance - The company reported revenues of approximately 303 million RMB, 240 million RMB, and 238 million RMB for the fiscal years ending in 2023, 2024, and the nine months ending September 30, 2025, respectively [4] - The total profit and comprehensive income for the same periods were approximately 79.5 million RMB, 33.9 million RMB, and 53.4 million RMB [6] - The gross profit margins for 2023, 2024, and the nine months ending September 30, 2025, were approximately 87.4%, 83.4%, and 87.4% [8] Industry Overview - Mitochondrial dysfunction is increasingly recognized as a common pathological mechanism for aging-related diseases, including cardiovascular diseases, neurodegenerative diseases, metabolic diseases, and immune aging [10] - The market size for mitochondrial medicine products in China is projected to grow from 9.5 billion RMB in 2020 to 17.9 billion RMB in 2024, with a compound annual growth rate (CAGR) of 17.1% [10] - It is expected that the market size will reach 308.1 billion RMB by 2035, with a CAGR of 29.5% from 2024 to 2035 [10]